The Aspen share price held up reasonably well on Tuesday after confirmation that the European Commission had launched a Europe-wide investigation into alleged price hiking of critical cancer drugs. Source: EU probes Aspen price-hiking allegations
The earnings growth projected by the company is unlikely to materialise as the drug pricing scandal grows Source: Aspen’s conduct hard to swallow
Aspen Pharmacare on Monday issued a statement welcoming reports that South Africa’s Competition Commission had agreed to take up a request from the country’s official opposition to investigate alleged anticompetitive conduct by the company. Source: Aspen welcomes DA-initiated price-fixing probe
Pharma major Cipla today said its arm Medpro South Africa (Pty) Limited has signed an agreement to acquire 100 per cent stake in Anmarate (Pty) Limited, South Africa, for around R26m. Source: Cipla acquires South Africa-based firm for R26m - Cape Business News
Rapid expansion has taken a toll at the generic pharmaceuticals giant, with disappointing results and high turnover Source: Big build-up, small payoff for Aspen
https://www.youtube.com/watch?v=XRFidu_r8hk
Africa’s biggest generic drug maker, Aspen Pharmacare, said on Thursday that it was intent on carving out a niche market in the US, one of the few remaining territories in which the Durban-based company has yet to make its presence felt in a big way. Source: Ambitious Aspen targets US market
Karsten Wellner, CEO at Ascendis Health, speaks to Business Day TV about the company’s first-half results. Source: BUSINESS DAY TV: It is proving difficult to find top people for our businesses
The group now earns more than three-quarters of its income from outside SA Source: Stronger rand is bitter medicine for Aspen Pharmacare
Ascendis, the healthcare conglomerate that has grown fast by acquisitions, is tilting at vibrant eastern Europe niche markets. Source: Ascendis looks to eastern Europe
